MedPath

Tillotts Pharma Ag

Tillotts Pharma Ag logo
🇸🇪Sweden
Ownership
Subsidiary
Established
1986-01-01
Employees
501
Market Cap
-
Website
http://www.tillotts.com

Clinical Trials

28

Active:15
Completed:13

Trial Phases

2 Phases

Phase 1:18
Phase 3:8

Drug Approvals

25

CANADA:7
NMPA:4
CIMA_AEMPS:4
+2 more agencies

Drug Approvals

Mesalazine Enteric-coated Tablets

Product Name
美沙拉嗪肠溶片
Approval Number
国药准字HJ20200006
Approval Date
Apr 15, 2025
NMPA

Mesalazine Enteric-coated Tablets

Product Name
美沙拉嗪肠溶片
Approval Number
国药准字HJ20200007
Approval Date
Apr 15, 2025
NMPA

Mesalazine Enteric-coated Tablets

Product Name
美沙拉嗪肠溶片
Approval Number
H20200007
Approval Date
Apr 23, 2020
NMPA

Mesalazine Enteric-coated Tablets

Product Name
美沙拉嗪肠溶片
Approval Number
H20200006
Approval Date
Apr 23, 2020
NMPA

Clinical Trials

Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials

Phase 1
18 (69.2%)
Phase 3
8 (30.8%)

Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules

First Posted Date
2016-09-22
Last Posted Date
2017-04-04
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
18
Registration Number
NCT02911298
Locations
🇨🇭

University Hospital Basel, Phase I Research Unit, Basel, Basel-Stadt, Switzerland

TP0501 - Pharmaco-Scintigraphic-Study

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: TP05 Coating A
Drug: TP05 Coating B
First Posted Date
2014-12-03
Last Posted Date
2014-12-03
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
18
Registration Number
NCT02306772

TP0502-Pharmaco-Scintigraphic-Study and Amendment

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: TP05 Coating D
Drug: TP05 Coating H
Drug: TP05 Coating E
First Posted Date
2014-12-03
Last Posted Date
2014-12-03
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
26
Registration Number
NCT02306785

TP0502-B-Pharmaco-Scintigraphic-Study

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2014-12-03
Last Posted Date
2014-12-04
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
9
Registration Number
NCT02306798

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

Phase 3
Completed
Conditions
Acute Ulcerative Colitis
Interventions
First Posted Date
2013-07-19
Last Posted Date
2018-08-08
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
817
Registration Number
NCT01903252
Locations
🇨🇭

Tillotts Pharma AG, Rheinfelden, Baslerstrasse 15, Switzerland

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.